JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2003; 41:1380-1386, doi:10.1016/S0735-1097(03)00121-9
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Galiè, N.
Right arrow Articles by Rubin, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galiè, N.
Right arrow Articles by Rubin, L.

CLINICAL STUDY: SYSTEMIC AND PULMONARY HYPERTENSION

Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension

Nazzareno Galiè, MD*,*, Alan L. Hinderliter, MD{dagger}, Adam Torbicki, MD{ddagger}, Thierry Fourme, MD§, Gerald Simonneau, MD§, Tomas Pulido, MD||, Nilda Espinola-Zavaleta, MD||, Guido Rocchi, MD*, Alessandra Manes, MD*, Robert Frantz, MD, Marcin Kurzyna, MD{ddagger}, Sherif F. Nagueh, MD#, Robyn Barst, MD**, Richard Channick, MD{dagger}{dagger}, Karl Dujardin, MD{ddagger}{ddagger}, Andrew Kronenberg, MD{dagger}, Isabelle Leconte, PhD§§, Maurizio Rainisio, PhD§§ and Lewis Rubin, MD{dagger}{dagger}

* Institute of Cardiology, University of Bologna, Italy
{dagger} Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
{ddagger} Department of Chest Medicine, Institute of Tuberculosis and Lung Disease, Warsaw, Poland
§ Division of Pulmonary and Critical Care Medicine, University of Paris-Sud, Paris, France
|| Instituto Nacional de Cardiologia, Mexico City, Mexico
Department of Cardiology, Mayo Clinic, Rochester, Minnesota, USA
# Baylor College of Medicine and the Methodist Hospital, Houston, Texas, USA
** Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, New York, USA
{dagger}{dagger} Division of Pulmonary and Critical Care Medicine, University of California, San Diego, California, USA
{ddagger}{ddagger} Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium
§§ Actelion Ltd., Allschwil, Switzerland

Manuscript received August 11, 2002; revised manuscript received December 20, 2002, accepted January 2, 2003.

* Reprint requests and correspondence: Dr. Nazzareno Galiè, Istituto di Cardiologia, Università di Bologna, via Massarenti, 9, 40138-Bologna, Italy.
n.galie{at}bo.nettuno.it

OBJECTIVES: The purpose of this study was to investigate the effects of bosentan (125 or 250 mg twice daily) on echocardiographic and Doppler variables in 85 patients with World Health Organization class III or IV pulmonary arterial hypertension (PAH).

BACKGROUND: Bosentan, an orally active dual endothelin-receptor antagonist, improves symptoms, exercise capacity, and hemodynamics in patients with PAH.

METHODS: Patients had primary pulmonary hypertension (84%) or PAH associated with connective tissue disease. Of these, 29 patients received placebo and 56 received bosentan (1:2 randomization). Six-minute walk tests and echocardiograms were performed at baseline and after 16 weeks of treatment.

RESULTS: Baseline characteristics were similar in the placebo and bosentan groups, and echocardiographic and Doppler findings were consistent with marked abnormalities of right ventricular (RV) and left ventricular (LV) structure and function that were due to PAH. The treatment effect on 6-min walking distance was 37 m in favor of bosentan (p = 0.036). Treatment effects of bosentan compared with placebo on other parameters were as follows: Doppler-derived cardiac index = +0.4 l/min/m2 (p = 0.007), LV early diastolic filling velocity = +10.5 cm/s (p = 0.003), LV end-diastolic area = +4.2 cm2 (p = 0.003), LV systolic eccentricity index = –0.12 (p = 0.047), RV end-systolic area = –2.3 cm2 (p = 0.057), RV:LV diastolic areas ratio = –0.64 (p = 0.007), Doppler RV index = –0.06 (p = 0.03), and percentage of patients with an improvement in pericardial effusion score = 17% (p = 0.05).

CONCLUSIONS: Bosentan improves RV systolic function and LV early diastolic filling and leads to a decrease in RV dilation and an increase in LV size in patients with PAH.

Abbreviations and Acronyms
  BREATHE-1
  Bosentan Randomized trial of Endothelin Antagonist Therapy for pulmonary hypertension
  LV
  left ventricle/ventricular
  PAH
  pulmonary arterial hypertension
  PPH
  primary pulmonary hypertension
  RV
  right ventricle/ventricular
  WHO
  World Health Organization




This article has been cited by other articles:


Home page
 Eur Respir JHome page
D. Stolz, H. Rasch, A. Linka, M. Di Valentino, A. Meyer, M. Brutsche, and M. Tamm
A randomised, controlled trial of bosentan in severe COPD
Eur. Respir. J., September 1, 2008; 32(3): 619 - 628.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
C. E. Ventetuolo, R. L. Benza, A. J. Peacock, R. T. Zamanian, D. B. Badesch, and S. M. Kawut
Surrogate and Combined End Points in Pulmonary Arterial Hypertension
Proceedings of the ATS, July 15, 2008; 5(5): 617 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
S G Haworth
The management of pulmonary hypertension in children
Arch. Dis. Child., July 1, 2008; 93(7): 620 - 625.
[Abstract] [Full Text] [PDF]

Home page
 Ann Rheum DisHome page
J Avouac, J Wipff, A Kahan, and Y Allanore
Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials
Ann Rheum Dis, June 1, 2008; 67(6): 808 - 814.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
J.G. Coghlan and J. Davar
How should we assess right ventricular function in 2008?
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H22 - H28.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
I. M. Lang
Management of acute and chronic RV dysfunction
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H61 - H67.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
N. Galie, A. Manes, M. Palazzini, L. Negro, S. Romanazzi, and A. Branzi
Pharmacological impact on right ventricular remodelling in pulmonary arterial hypertension
Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H68 - H74.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. Huez, F. Roufosse, J-L. Vachiery, A. Pavelescu, G. Derumeaux, J-C. Wautrecht, E. Cogan, and R. Naeije
Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension?
Eur. Respir. J., November 1, 2007; 30(5): 928 - 936.
[Abstract] [Full Text] [PDF]

Home page
 ERRHome page
S. P. Gaine and J. Behr
Confidence from experience: dual endothelin receptor antagonism in PAH
Eur. Respir. Rev., August 1, 2007; 16(102): 1 - 2.
[Full Text] [PDF]

Home page
 ERRHome page
J. S. R. Gibbs
Making a diagnosis in PAH
Eur. Respir. Rev., August 1, 2007; 16(102): 8 - 12.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. Torbicki
Cardiac magnetic resonance in pulmonary arterial hypertension: a step in the right direction
Eur. Heart J., May 5, 2007; (2007) ehm074v1.
[Full Text] [PDF]

Home page
 Eur Heart JHome page
S. A. van Wolferen, J. T. Marcus, A. Boonstra, K. M.J. Marques, J. G.F. Bronzwaer, M. D. Spreeuwenberg, P. E. Postmus, and A. Vonk-Noordegraaf
Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension
Eur. Heart J., May 2, 2007; 28(10): 1250 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos
Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year study
Heart, March 1, 2007; 93(3): 350 - 354.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
Q. Ruan and S. F. Nagueh
Clinical Application of Tissue Doppler Imaging in Patients With Idiopathic Pulmonary Hypertension
Chest, February 1, 2007; 131(2): 395 - 401.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EchocardiogrHome page
N. Collins, B. Bastian, L. Quiqueree, C. Jones, R. Morgan, and G. Reeves
Abnormal pulmonary vascular responses in patients registered with a systemic autoimmunity database: Pulmonary Hypertension Assessment and Screening Evaluation using stress echocardiography (PHASE-I)
Eur J Echocardiogr, December 1, 2006; 7(6): 439 - 446.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. R. Forfia, M. R. Fisher, S. C. Mathai, T. Housten-Harris, A. R. Hemnes, B. A. Borlaug, E. Chamera, M. C. Corretti, H. C. Champion, T. P. Abraham, et al.
Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., November 1, 2006; 174(9): 1034 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
N. F. Voelkel, R. A. Quaife, L. A. Leinwand, R. J. Barst, M. D. McGoon, D. R. Meldrum, J. Dupuis, C. S. Long, L. J. Rubin, F. W. Smart, et al.
Right Ventricular Function and Failure: Report of a National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure
Circulation, October 24, 2006; 114(17): 1883 - 1891.
[Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
B. Battistini, N. Berthiaume, N. F. Kelland, D. J. Webb, and D. E. Kohan
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel "-Sentan" Class of Drug.
Experimental Biology and Medicine, June 1, 2006; 231(6): 653 - 695.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Fijalkowska, M. Kurzyna, A. Torbicki, G. Szewczyk, M. Florczyk, P. Pruszczyk, and M. Szturmowicz
Serum N-Terminal Brain Natriuretic Peptide as a Prognostic Parameter in Patients With Pulmonary Hypertension
Chest, May 1, 2006; 129(5): 1313 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S C Apostolopoulou, A Manginas, D V Cokkinos, and S Rammos
Effect of the oral endothelin antagonist bosentan on the clinical, exercise, and haemodynamic status of patients with pulmonary arterial hypertension related to congenital heart disease
Heart, November 1, 2005; 91(11): 1447 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. Piazza and S. Z. Goldhaber
The Acutely Decompensated Right Ventricle: Pathways for Diagnosis and Management
Chest, September 1, 2005; 128(3): 1836 - 1852.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1292 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra
Pulmonary Arterial Hypertension: The Key Role of Echocardiography
Chest, May 1, 2005; 127(5): 1836 - 1843.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
O. Sitbon, V. Gressin, R. Speich, P. S. Macdonald, M. Opravil, D. A. Cooper, T. Fourme, M. Humbert, J.-F. Delfraissy, and G. Simonneau
Bosentan for the Treatment of Human Immunodeficiency Virus-associated Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., December 1, 2004; 170(11): 1212 - 1217.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
S. M. Lowson
Alternatives to nitric oxide
Br. Med. Bull., November 5, 2004; 70(1): 119 - 131.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Humbert, O. Sitbon, and G. Simonneau
Treatment of Pulmonary Arterial Hypertension
N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436.
[Full Text] [PDF]

Home page
 Ann Rheum DisHome page
E Hachulla and J G Coghlan
A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism
Ann Rheum Dis, September 1, 2004; 63(9): 1009 - 1014.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki
End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 48S - 55S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. N. Channick, O. Sitbon, R. J. Barst, A. Manes, and L. J. Rubin
Endothelin receptor antagonists in pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 62S - 67S.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
N. Galie, W. Seeger, R. Naeije, G. Simonneau, and L. J. Rubin
Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension
J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 81S - 88S.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S.M. Kawut and H.I. Palevsky
New answers raise new questions in pulmonary arterial hypertension
Eur. Respir. J., June 1, 2004; 23(6): 799 - 801.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J., June 1, 2004; 23(6): 947 - 953.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. R. Wilkins
Selective or Nonselective Endothelin Receptor Blockade in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med., February 15, 2004; 169(4): 433 - 434.
[Full Text] [PDF]

Home page
 Cardiovasc ResHome page
N. Galie, A. Manes, and A. Branzi
The endothelin system in pulmonary arterial hypertension
Cardiovasc Res, February 1, 2004; 61(2): 227 - 237.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Mehta
Drug Therapy for Pulmonary Arterial Hypertension: What's on the Menu Today?
Chest, December 1, 2003; 124(6): 2045 - 2049.
[Full Text] [PDF]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.